{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal Lomecel-B",
            "NStudiesAvail": 430108,
            "NStudiesFound": 5,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 5,
            "FieldList": [
                  "Acronym",
                  "AgreementOtherDetails",
                  "AgreementPISponsorEmployee",
                  "AgreementRestrictionType",
                  "AgreementRestrictiveAgreement",
                  "ArmGroupDescription",
                  "ArmGroupInterventionName",
                  "ArmGroupLabel",
                  "ArmGroupType",
                  "AvailIPDComment",
                  "AvailIPDId",
                  "AvailIPDType",
                  "AvailIPDURL",
                  "BaselineCategoryTitle",
                  "BaselineClassDenomCountGroupId",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "Acronym": [
                              "HERA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single dose of 20 million Longeveron Mesenchymal Stem Cells (LMSCs) will be delivered followed by vaccination with Fluzone High-Dose at 1 week post-infusion.",
                              "Single dose of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) followed by vaccination with Fluzone High-Dose at either 1 week (Cohort B) or 4 weeks (Cohort C) post infusion.",
                              "2 cohorts to receive a single infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort A: 30 subjects) or placebo (Cohort B:30 subjects) followed by vaccination with Fluzone High-Dose."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Fluzone High Dose Vaccine",
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Fluzone High Dose Vaccine",
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Fluzone High Dose Vaccine"
                        ],
                        "ArmGroupLabel": [
                              "Pilot Phase- Cohort A",
                              "Pilot Phase Cohort B & C",
                              "Double-Blind,Randomized,Placebo Phase"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02982915"
                        ]
                  },
                  {
                        "Rank": 2,
                        "Acronym": [
                              "ELPIS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "10 consecutive HLHS patients will be enrolled and treated with Longeveron Mesenchymal Stem Cells (LMSCs). A single administration of LMSCs will be performed via intramyocardial injections during the Stage II (BDCPA) surgery. Dosing is based on body weight. Each LMSC-treated patient will be given 2.5 x 105 LMSCs per kg of body weight. The entire dose of the cells will be roughly 600 microliters.",
                              "Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial.",
                              "Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Longeveron Mesenchymal Stem Cells",
                              "Biological: Longeveron Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Cohort A - Phase 1 (Open Label)",
                              "Cohort B - Phase 2 Treatment Group",
                              "Cohort C - Phase 2 Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03525418"
                        ]
                  },
                  {
                        "Rank": 3,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cohort 1 (10 subjects) Target dose 20 million Longeveron Mesenchymal Stem Cells (LMSCs) via peripheral intravenous infusion.",
                              "Cohort 2 (10 subjects) Target dose 100 million Longeveron Mesenchymal Stem Cells (LMSCs)via peripheral intravenous infusion.",
                              "Cohort 3 (5 subjects) Placebo (Plasmalyte A and 1% human serum albumin (HSA)) via peripheral intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Longeveron Mesenchymal Stem Cells",
                              "Biological: Longeveron Mesenchymal Stem Cells",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Cohort 1",
                              "Cohort 2",
                              "Cohort 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02600130"
                        ]
                  },
                  {
                        "Rank": 4,
                        "Acronym": [
                              "RECOVER"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 1: 25 subjects treated with up to 3 doses of 100 million LMSCs.",
                              "Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 2: 10 subjects treated with up to 3 doses of Placebo.",
                              "Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 3: 25 subjects treated with up to 3 doses of 100 million LMSCs.",
                              "Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 4: 10 subjects treated with up to 3 doses of Placebo."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Other: Placebo",
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Cohort 1 (SARS-CoV-2): Arm 1 (LMSCs)",
                              "Cohort (SARS-CoV-2): Arm 2 (Placebo)",
                              "Cohort 2 (Flu): Arm 3 (LMSCs)",
                              "Cohort 2 (Flu): Arm 4 (Placebo)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04629105"
                        ]
                  },
                  {
                        "Rank": 5,
                        "Acronym": [
                              "ELPISII"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants randomized to receive Lomecel-B injections during their Stage II palliation.",
                              "Participants randomized to receive no study intervention during their Stage II palliation."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Lomecel-B medicinal signaling cells"
                        ],
                        "ArmGroupLabel": [
                              "Lomecel B Group",
                              "No Study Intervention Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04925024"
                        ]
                  }
            ]
      }
}